https://www.selleckchem.com/pr....oducts/Vorinostat-sa
No approved therapies directly target retinal ganglion cells (RGCs) for neuroprotection or neuroenhancement in glaucoma. Recombinant human nerve growth factor (rhNGF) has been shown to promote RGC survival and function in animal models of optic neuropathy. Here we evaluate the safety, tolerability, and efficacy of short-term, high-dose rhNGF eye drops versus placebo in a cohort of glaucoma patients. This was a prospective, phase 1b, single-center, randomized, double-masked, vehicle-controlled, parallel-group study. This study wa
Like
Comment
Share
